GP Extended Action Triptorelin
The purpose of this study is to demonstrate that treatment with a 6-monthly injection of hormone therapy is as good and as well tolerated as the standard 3-monthly hormone therapy injections available for treating prostate cancer. The study will also aim to answer whether both doctors and patients would prefer treatment with a 6-monthly injection rather than injections every 3 months.
Prostate Cancer
DRUG: Decapeptyl® SR 22.5mg|DRUG: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
Percentage of Participants Maintaining Biochemical Castration, Patients with serum total testosterone (STT) level lower than 0.5 ng/mL after 6 months of treatment., 6 months
Percentage of Participants Maintaining Biochemical Castration After 12 Months of Treatment., Patients with serum total testosterone (STT) level lower than 0.5 ng/mL, 12 months after randomisation.., 12 months|Percentage of Participants Demonstrating Stable Prostate-specific Antigen (PSA) Levels, Stable PSA level was noted as value either lower or less than 25% higher than the baseline value, or PSA value ≤0.5 ng/mL higher than the baseline value, if value ≥25% higher than the baseline value., 6 and 12 months|Change From Baseline in Quality of Life Using EuroQol 5 Dimensions 5 Levels [EQ-5D-5L] Questionnaire., The EQ-5D-5L questionnaire consisted of a description of raw data which comprised of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension had five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The visual analogical scale of the EQ-5D-5L questionnaire was numbered from 0 to 100 (0 meaning the worst health the patient can imagine and 100 the best health the patient can imagine)., Baseline and Month 12|Change From Baseline in Patient Satisfaction With Medication Using Treatment Satisfaction Questionnaire for Medication (TSQM Version II), TSQM comprised of four dimensions: effectiveness, side effects, convenience and overall global satisfaction. Each score ranged from 0 to 100. For effectiveness, convenience and overall global satisfaction scores, 0 indicated an extreme dissatisfaction and 100 indicated an extreme satisfaction. For side effects score, 0 indicated an extreme dissatisfaction and 100 indicated no dissatisfaction at all., 6 and 12 month|Patient Satisfaction With Treatment., Using a non-validated study-specific descriptive Likert-type scale (with no units) comprising a simple six-question patient questionnaire., Month 12|Percentage of Participants Who Changed Injection Frequency After Completion of the Study, Month 12
The purpose of this study is to demonstrate that treatment with a 6-monthly injection of hormone therapy is as good and as well tolerated as the standard 3-monthly hormone therapy injections available for treating prostate cancer. The study will also aim to answer whether both doctors and patients would prefer treatment with a 6-monthly injection rather than injections every 3 months.